Form 10-Q Imprimis Pharmaceuticals For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Imprimis Pharma (IMMY) Misses Q2 EPS by 7c
August 12, 2015 4:49 PM EDTImprimis Pharma (NASDAQ: IMMY) reported Q2 EPS of ($0.39), $0.07 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $2 million versus the consensus estimate of $2.13 million.
For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.
... More